Raday Gilead's Form 4 filing
RedHill Biopharma Ltd. (RDHL) · filed Apr 22, 2026
- Accession no.
- 0001178913-26-002183
- Filed
- Apr 22, 2026
- Trade date
- Apr 6, 2026
- Filing delay
- 16 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. It was filed 16 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Raday GileadCIK 0002113137 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 6, 2026 | Ordinary Shares | SSaleDisposed | −15,740,000 | $0.00 | $0 | 261,060,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 6, 2026 | Ordinary Shares | MOption exerciseAcquired | +30,780,000 | $0.00 | $0 | 76,150,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.